Healthy men test new allergy drug version in safety study
NCT ID NCT07246252
First seen Nov 25, 2025 · Last updated May 19, 2026 · Updated 23 times
Summary
This study tested a new version of the allergy drug omalizumab (called CMAB007) against the approved drug Xolair. It involved 114 healthy Chinese men who received a single dose of one of the two drugs. The goal was to compare how the drugs move through the body, their safety, and whether the body reacts to them differently.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui Central Hospital, Shanghai
Shanghai, China
Conditions
Explore the condition pages connected to this study.